Defence Therapeutics Inc.
DTCFF
$0.35
-$0.02-5.41%
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.16M | 2.30M | 1.80M | 1.71M | 2.47M |
| Depreciation & Amortization | 39.20K | 44.70K | 50.70K | 51.90K | 73.50K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.28M | 2.98M | 2.42M | 2.34M | 3.32M |
| Operating Income | -3.28M | -2.98M | -2.42M | -2.34M | -3.32M |
| Income Before Tax | -4.57M | -3.32M | -2.80M | -2.73M | -2.88M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -4.57 | -3.32 | -2.80 | -2.73 | -2.88 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.57M | -3.32M | -2.80M | -2.73M | -2.88M |
| EBIT | -3.28M | -2.98M | -2.42M | -2.34M | -3.32M |
| EBITDA | -3.25M | -2.95M | -2.38M | -2.29M | -3.26M |
| EPS Basic | -0.08 | -0.06 | -0.05 | -0.06 | -0.06 |
| Normalized Basic EPS | -0.05 | -0.04 | -0.03 | -0.03 | -0.04 |
| EPS Diluted | -0.08 | -0.06 | -0.05 | -0.06 | -0.06 |
| Normalized Diluted EPS | -0.05 | -0.04 | -0.03 | -0.03 | -0.04 |
| Average Basic Shares Outstanding | 223.82M | 214.00M | 204.84M | 195.65M | 186.45M |
| Average Diluted Shares Outstanding | 223.82M | 214.00M | 204.84M | 195.65M | 186.45M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |